Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2025 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizio
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to The Report
Fundraising

BioNTech

BioNTech Raises $325M in Follow-on Offering

2008
Founded
5000+
Employees
An der Goldgrube 12, Mainz 55131, Germany
Updated July 6, 2024
2 min read

Quick Facts

BioNTech Raises $325M in Follow-on Offering


BioNTech has successfully raised $325M in a Follow-on Offering at a $45B valuation led by Strüngmann Family Office, MIG, Salvia, AT Impf, Pfizer.


Company Overview


BioNTech is a Biotech company headquartered in An der Goldgrube 12, Mainz 55131, Germany, founded in 2008 with 5000+ employees.


Immunotherapy and mRNA vaccines


Fundraising Details


  • Amount Raised: $325M
  • Round Type: Follow-on Offering
  • Valuation: $45B
  • Date: 2024-07-06
  • Investors: Strüngmann Family Office, MIG, Salvia, AT Impf, Pfizer

About BioNTech


Immunotherapy and mRNA vaccines The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: An der Goldgrube 12, Mainz 55131, Germany
  • Founded: 2008
  • Team Size: 5000+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in BioNTech's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. BioNTech's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $45B valuation marks an important milestone for BioNTech, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, BioNTech is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-07-06. For more information about BioNTech, visit their headquarters at An der Goldgrube 12, Mainz 55131, Germany.

Topics

Fundraising(2912)BiotechFollow-on OfferingBioNTech

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million